Latest financial market updates and expert analysis
Analysis The telemedicine platform Hims & Hers is navigating one of the most turbulent stretches in its history, caught between a widening regulatory offensive and an aggressive push into the booming...
The fairy tale had a good run. For years, Novo Nordisk was the undisputed king of the weight-loss boom, its...
The semiconductor maker’s stock has spent the past month giving back a substantial chunk of its 2026 gains, and Wednesday’s...
The disconnect has rarely been starker: Micron Technology just posted the best quarterly results in its corporate history, yet the...
The numbers landing on Shell’s desk this earnings season tell a story of extraordinary tailwinds. Net income for the first...
European investors have been pouring money into global equity ETFs at an unprecedented clip, yet the MSCI World tracker now...
The Swiss asset manager’s decision to offload its majority holding in Polish convenience-store chain Żabka to Canada’s Alimentation Couche-Tard lands...
The gap between XPeng’s operational momentum and its stock price has rarely been wider. The electric vehicle maker just posted...
For nearly eight years, Alnylam has enjoyed something almost unheard of in biotech: a drug with no true rival for...
The numbers coming out of Cupertino last week were, by any conventional measure, exceptional. Revenue hit a record $109.4 billion...
A company that once promised investors hundreds of autonomous kitchen robots in the field by year-end is now targeting just...
